Summit Therapeutics SMMT Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $8.24M-49.7% | $16.37M+236% | $4.87M+14.2% | $4.27M-44.5% | $7.68M-52.8% | ||
| $492.22M+0.8% | $488.18M— | $0— | $0-100% | $149.79M-51.3% | ||
| $616.6M-14.4% | $720.3M+192% | $246.47M-20.3% | $309.24M-16.6% | $370.75M-12.5% | ||
| $1.66M+57.1% | $1.06M+30.7% | $810K+17.4% | $690K+5.8% | $652K+157% | ||
| $1.97M-1.8% | $2M+0.1% | $2M-2.0% | $2.04M+6.0% | $1.92M+3.2% | ||
| $647.86M-13.8% | $751.18M+187% | $261.73M-19.2% | $324.04M-15.6% | $383.82M-11.9% | ||
| $27.55M+35.8% | $20.29M-8.8% | $22.25M-3.2% | $22.98M+360% | $4.99M+7.7% | ||
| $83.27M+14.1% | $72.99M+12.4% | $64.93M+7.6% | $60.33M+73.0% | $34.88M-16.4% | ||
| $101.92M+10.4% | $92.32M+32.9% | $69.47M+7.5% | $64.6M+63.6% | $39.49M-15.6% | ||
| 1B0.0% | 1B0.0% | 1B0.0% | 1B0.0% | 1B+13,457% | ||
| -$2.48B-8.3% | -$2.29B-10.6% | -$2.07B-12.6% | -$1.84B-44.3% | -$1.28B-5.2% | ||
| $545.93M-17.1% | $658.86M+243% | $192.26M-25.9% | $259.44M-24.7% | $344.33M-11.4% | ||
| $647.86M-13.8% | $751.18M+187% | $261.73M-19.2% | $324.04M-15.6% | $383.82M-11.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Summit Therapeutics's total assets?
- Summit Therapeutics (SMMT) holds $647.9M in total assets, up 68.8% year over year.
- How much debt does Summit Therapeutics have?
- Summit Therapeutics carries $20.0M in total debt against $545.9M of shareholders' equity, a debt-to-equity ratio of 0.04.
- How much cash does Summit Therapeutics have?
- Summit Therapeutics holds $8.2M in cash and equivalents.
- Can Summit Therapeutics cover its short-term obligations?
- Its current ratio is 7.41 — current assets exceed current liabilities.
- Where does Summit Therapeutics's balance sheet data come from?
- Every line is extracted from Summit Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.